POSSIBLE FUTURE THERAPEUTIC STRATEGIES OF TREATMENT OF HNSCC
Gene therapy
Virus directed enzyme prodrug therapy: induction of herpes simplex virus “thymidine kinase gene” into tumour cell leading to expression of thymidine kinase which halts DNA synthesis and decrease cell growth.
Tissue inhibitors of matrix metalloprotienase (TIMP): Tumour cell produce both metalloprotinase and their tissue inhibitor (TIMP) causing imbalance between these two leading to proteolysis and spread of the tumour.
Antiangiogenesis agent: Angiogenesis responsible for tumour growth and invasion.